Please assess the completion status of the following clinical trial:

Trial Title: C-Cure Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 and \< 75 years old;~* Subject has Heart Failure, New York Heart Association (NYHA) class II or class III with LVEF \> 15% and ≤ 40% as assessed by transthoracic echocardiography;~* Subject has ischemic heart disease;~* Subject has an identifiable (by transthoracic echocardiography) area of transmural scar within the left ventricle;~* Subject is on optimal and stable medical therapy for more than 2 months;~* Subject is willing and able to undergo an ICD implantation, prior to receiving C-Cure™ or already has an ICD implanted;~* Subject agrees to comply with all follow-up evaluations;~* Subject has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent.~Exclusion Criteria:~* Subject has been treated with cell-based therapy;~* Subject has myocardial revascularization by PCI or CABG within 2 months prior to enrolment;~* Subject has had an MI within 2 months prior to enrolment;~* Subject is planned for PCI, CABG or any cardiac surgery;~* Subject has received a biventricular pacemaker within 6 month prior to enrolment;~* Subject has moderate to severe aortic valve heart disease, aortic or mitral prosthetic valve;~* Subject has a significant mitral valve insufficiency (Effective Regurgitant Orifice (ERO) \> 0.2 cm²) with possibility of mitral valve surgery;~* Subject has left ventricular thrombus;~* Subject has LV aneurysma or is a candidate for surgical aneurysmectomy;~* Subject LV ventricular wall thickness is \< 5 mm in the target territory;~* Subject has proven high grade atrioventricular block or sustained ventricular tachyarrhythmias;~* Subject has an hemodynamically significant congenital heart disorder;~* Subject has clinical evidence for infection or active malignancy;~* Subject has known stable chronic kidney dysfunction with serum creatinine \> 2.5 mg/dL at two occasions during the screening period;~* Subject has experienced severe adverse reaction/allergies to contrast agents;~* Subject has atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree, that could impede or preclude the safe retrograde passage of the delivery catheter, in the judgment of the investigator;~* Subject is on chronic immunosuppressive transplant therapy;~* Subject had an autologous or allogenic bone marrow or peripheral stem cell transplant or prior solid organ transplantation;~* Subject has a multisystem disease;~* Subject has been tested positive for Human Immunodeficiency Virus (HIV 1 or HIV 2), Hepatitis B Virus (HBV), Hepatitis C (HCV) and/or syphilis;~* Women of child bearing potential;~* Subject has life expectancy \< 1 year from non heart failure related causes;~* Subject suffers from morbid obesity (Body Mass Index (BMI) \> 40);~* Subject has a recent history of alcohol or drug abuse;~* Subject has any other surgical or medical condition that, in the judgment of the investigator might warrant exclusion or be contraindicated for safety reasons;~* Subject is currently participating in another trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Optimal standard of care + C-Cure
- 2 (Type: NO_INTERVENTION): Optimal standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete